A Phase 1 Dose-Escalation Study of ARRY-520, a KSP Inhibitor, in Patients with Advanced Myeloid Leukemias

BACKGROUND: ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis. METHODS: A Phase 1 trial was conducted to establish the safety and the maximum tolerated dose (MTD) of ARRY-520 given as a 1-hour infusion in either...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Khoury, Hanna Jean, Garcia-Manero, Guillermo, Borthakur, Gautam, Kadia, Tapan, Foudray, Maria Cielo, Arellano, Martha, Langston, Amelia, Bethelmie-Bryan, Beverly, Rush, Selena, Litwiler, Kevin, Karan, Sharon, Simmons, Heidi, Marcus, Adam I., Ptaszynski, Mieke, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984525/
https://ncbi.nlm.nih.gov/pubmed/22139909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26664
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados